Skip to main content

Table 2 Prevalence of viral suppression, crude and adjusted odds ratios (with 95%CI) summarizing the relationship between selected risk factors and viral suppression during a 48 week follow-up period among HIV-infected children in Uganda (N = 142)

From: Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load

Characteristic

Viral suppression by week

Crude Odds Ratio

Adjusted Odds Ratio

 

Baseline

n (%)

24 Weeks

n (%)

48 Weeks

n (%)

OR (95% CI)

aOR (95% CI)

Monitoring arm

 Immunologic

46 (65)

43 (68)

46 (70)

Ref

Ref a

 Immunologic & Virologic

46 (65)

43 (65)

47 (69)

0.88 (0.46; 1.69)

1.06 (0.47; 2.42)

ARV Change

 No

 

78 (66)

77 (69)

Ref

Ref

 Yes

 

8 (80)

16 (70)

1.52 (0.59; 3.89)

0.85 (0.27; 2.73)

Study Site

 Mulago

43 (61)

38 (59)

43 (63)

Ref

Ref b

 Nsambya

49 (68)

48 (74)

50 (76)

1.56 (0.82; 2.99)

0.70 (0.25; 1.96)

Sex

 Female

39 (64)

34 (63)

41 (69)

Ref

Ref c

 Male

53 (65)

52 (69)

52 (69)

1.12 (0.58; 2.15)

1.01 (0.45; 2.26)

WHO Stage

 1

16 (73)

12 (63)

14 (66)

Ref

Ref d

 2

38 (67)

40 (78)

40 (74)

1.14 (0.42; 3.09)

0.63 (0.17; 2.26)

 3

33 (61)

31 (61)

33 (66)

0.74 (0.28; 1.98)

0.49 (0.14; 1.66)

 4

5 (56)

3 (38)

6 (67)

0.55 (0.13; 2.32)

0.28 (0.05; 1.63)

NVP Exposure

 Yes

27 (51)

28 (55)

28 (56)

Ref

Ref e

 No

56 (74)

47 (72)

55 (77)

2.61 (1.31; 5.21)**

2.75 (1.19; 6.37)**

 Unknown

9 (69)

11 (85)

10 (77)

2.92 (0.83; 10.32)

 

In utero ART

 Yes

27 (63)

25 (60)

24 (57)

Ref

Ref f

 No

51 (62)

47 (65)

54 (72)

1.37 (0.67; 2.77)

1.20 (0.53; 2.74)

 Unknown

14 (82)

24 (93)

15 (88)

5.10 (1.26; 20.61)*

Age (years)

   

1.01 (0.90; 1.16)

1.19 (0.97; 1.48)g

ART duration (years)

   

0.70 (0.56; 0.88)**

0.67 (0.49; 0.91)h*

CD%/cell count

   

1.03 (0.99; 1.07)

1.09 (1.04; 1.15)i*

Log (Absolute CD4)

   

2.82 (1.39, 5.69)**

2.75 (1.17; 15.18)i*

BMI-for-age Z:

   

0.79 (0.61; 1.01)

0.85 (0.62; 1.15)j

Weight-for-age Z:

   

0.96 (0.73; 1.28)

1.11 (0.75; 1.64)j

Height-for-age Z:

   

1.21 (0.91; 1.61)

1.33 (0.91; 1.93)j

  1. *p < 0.05; **p < 0.01
  2. aAdjusted for week, location, sex, age, NVP exposure, In-utero ART, ART duration, Absolute CD4
  3. bAdjusted for study arm, week, sex, age, NVP exposure, In-utero ART, ART duration, Absolute CD4
  4. cAdjusted for study arm, week, Absolute CD4
  5. dAdjusted for study arm, week, location, sex, and in-utero ART
  6. eAdjusted for study arm, week, location, WHO stage, in-utero ART, ART duration and BMI-for-age Z
  7. fAdjusted for study arm, week, and location
  8. gAdjusted for study arm, week, location, sex, NVP exposure, In-utero ART, and BMI-for-age Z
  9. hAdjusted for study arm, week, location, WHO stage, NVP exposure, In-utero ART, and BMI-for-age Z
  10. iAdjusted for study arm, week, location, sex, NVP exposure, In-utero ART, and BMI-for-age Z
  11. jAdjusted for study arm, week, location, sex, NVP exposure, In-utero ART, ART duration and Absolute CD4
  12. ARV Change – Time dependent (varying) variable (adjusted for study arm, week, location, NVP exposure, ART duration and baseline absolute CD4 count)